Skip to content
  • Career
  • Support
  • Contact Us
Menu
  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Search
Close
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get a Quote
    • Get Set Up
  • News & Events
    • News
    • Events
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us
  • All posts

AMRA Medical’s MRI Analysis—A New Research Paradigm Delivering Results in FSHD Clinical Trial

  • July 14, 2021

[Click on the image above to view the video]

AMRA’s quantitative whole-body MRI analysis used in the ReDUX4 clinical trial.

 

LINKÖPING, Sweden, July 14, 2021 — AMRA announced today that its magnetic resonance imaging (MRI) based method has sufficient sensitivity to detect disease progression at the muscular level in ReDUX4: a multicenter Phase 2b clinical trial testing the safety and efficacy of Losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD). The study introduced a powerful new method in MR image analysis, delivering a new paradigm in neuromuscular disease clinical trials for clinical researchers to consider.

AMRA’s quantitative measures for evaluating muscle health, including muscle fat infiltration to volumetrically evaluate the amount of fat within functional muscles, were used in ReDUX4. The clinical trial, launched by Fulcrum Therapeutics in 2019, enrolled 80 patients across 17 sites in 4 countries including the United States. Participants in the ReDUX4 trial were assessed with quantitative full body, whole muscle MRI, providing a holistic understanding of what is going on inside the muscles. Recently announced by Fulcrum, Losmapimod-treated participants showed decreased disease progression in the composite measure of muscle fat infiltration as measured in intermediate muscles (those most likely to change).

“We are thrilled about the ReDUX4 results. Not only do they propel a potential treatment forward for people living with FSHD, but the reduction in muscle fat infiltration and correlating benefit with several other measures reflects the power of our MRI-based muscle assessment methods in neuromuscular disease clinical trials. We are excited to bring these benefits to other teams to help them push their research forward and address the needs of these devastating diseases,” said Eric Converse, CEO of AMRA Medical.

AMRA’s advanced MRI methods and analysis can potentially help detect changes prior to individuals experiencing functional difficulties. This is particularly powerful when paired in clinical trials with functional outcome assessments, such as the Timed Up and Go (TUG), in clinical trials because researchers can assess disease severity at multiple levels and connect it to FSHD-relevant clinical endpoints. Further, AMRA’s whole muscle MR imaging and analysis, proximal to distal, in the whole body, led to a personalized set of muscles to follow over time, enabling researchers to capture disease heterogeneity—a longstanding challenge in neuromuscular disease research.

Setting a new standard in neuromuscular disease research, the ReDUX4 results demonstrate how MRI advancements can detect pathological changes in muscle, providing critical information about disease severity, disease progression, and the effect of a drug on muscle health.

Learn more about AMRA Medical’s MRI-based services for neuromuscular research at www.amramedical.com or connect with our team experts for a detailed discussion at info@amramedical.com.

  • All posts
Research Services
Follow us
Linkedin Twitter Facebook

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support
  • Data Privacy Policy
  • Cookie Policy
  • Data Privacy Policy
  • Cookie Policy

Newsletter

    © 2023 AMRA Medical AB

    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}
    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}